National Guideline Clearinghouse | Rituximab for the first-line treatment of chronic lymphocytic leukaemia.

Guideline Title
Rituximab for the first-line treatment of chronic lymphocytic leukaemia.

Bibliographic Source(s)
National Institute for Health and Clinical Excellence (NICE). Rituximab for the first-line treatment of chronic lymphocytic leukaemia. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Jul. 33 p. (Technology appraisal guidance; no. 174).

Guideline Status
This is the current release of the guideline.


full-text:
National Guideline Clearinghouse | Rituximab for the first-line treatment of chronic lymphocytic leukaemia.